Prelude Therapeutics Inc 8-K

What Happened

• Prelude Therapeutics, Inc. filed a Current Report on Form 8‑K on January 9, 2026 under Item 7.01 (Regulation FD Disclosure) to furnish investor presentation materials management will use in investor presentations starting January 9, 2026. The presentation is attached as Exhibit 99.1 to the filing. The report was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer, on January 9, 2026.
• The company states the information in the 8‑K and Exhibit 99.1 is being furnished (not “filed”) for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other securities filings.

Key Details

• Filing date: January 9, 2026 (Form 8‑K).
• Exhibit included: Exhibit 99.1 — investor presentation materials.
• Intended use: management presentations commencing January 9, 2026.
• Disclosure status: furnished under Reg FD and explicitly not deemed “filed” or incorporated by reference.

Why It Matters

• This is a routine disclosure that signals Prelude will be presenting to investors and the market; the attached presentation may include updates on pipeline, strategy, or milestones that investors should review.
• Because the materials are furnished (not filed), the company clarifies they are not incorporated into its other SEC filings and the filing does not itself report earnings, financings, or executive changes. Investors should view the attached presentation directly for any substantive updates.